ZOTEFOAMS PLC (ZTF) — Investment Research Note

Executive summary

Zotefoams is a UK-listed specialty foam manufacturer that uses proprietary nitrogen-expansion technology to produce high-performance polyolefin and technical foams for footwear (predominantly Nike), aerospace/space, transport, insulation and industrial packaging. Over the covered period the group has re-shaped from a two-product foam business into a market-vertical structure with international manufacturing (UK, US, Poland, Spain via OKC, Vietnam in commissioning), revenue growing from ~£100m in 2021 to ~£158m in 2025 with FY2026 consensus at £190.8m/£26.3m adj PBT and a medium-term target of >£230m revenue and >£40m operating profit by FY2029. The single most important issue for valuation today is execution of the Vietnam/OKC/UK-restructuring transition — the shares are trading on ~10–11× FY26 adj EPS with a healthy balance sheet, so upside depends on the company delivering the promised 2028+ inflection rather than on any AI narrative.

Fair value estimate

• Fair value range: 470p – 580p per share (implied market cap ~£232m – £286m)
• Methodology: forward P/E on adjusted earnings, cross-checked against the FY2029 operating-profit ambition discounted back.
• Key assumptions: FY2026 adj PBT £26.3m in line with company-flagged consensus 2026-08 H1; ~19–20% effective tax → adj NI ~£21m → adj EPS ~43p; apply 11–13.5× to reflect mid-single-digit organic growth, quality specialty-chemical profile and Nike/transition risk. Cross-check: FY2029 op profit target £40m → ~£30m NI → ~60p EPS; at 12× that is ~720p, discounted at 10% p.a. for three years = ~540p — inside the range above.
• Vs current market cap £219.4m / 445p: fair value midpoint ~525p implies an implied cap of ~£259m.
• Absolute upside: ~18% to midpoint (range: +6% to +30%).

Sector context

• ICB classification: Basic Materials / Chemicals — specifically specialty polymer processing. Confirmed.
• Quality/growth/leverage profile is in line to slightly above typical UK specialty-chemicals peers: gross margin ~35–36% and adj operating margin ~17% are respectable but below very high-end names; leverage <1× EBITDA is conservative.
• Listed peers: Victrex (VCT) — high-performance polymers with aerospace/medical exposure; Croda (CRDA) — specialty chemicals; Synthomer (SYNT) — polymer emulsions/specialties (more commodity-exposed).

Investment thesis (3 bullets)

• Transition to a bigger, more balanced business is underway. H1 2026 revenue +23% to £95.2m with adj op profit +34% and margin +130bps; underlying organic growth 4–6% ex-OKC, doubling of Asia and record North America performance 2026-08 interim. Company reiterates £230m rev/£40m op profit by FY2029.
• Fair-to-cheap valuation with a clean balance sheet. ~10–11× FY26 adj EPS, 0.98× leverage, £50m facility headroom, refinanced £90m RCF (from £50m) in January 2026 2026-08 interim. UK restructuring targets ~£4m annualised savings with <1yr payback 2026-08 interim.
• Structural aerospace/space, T-FIT and OKC add optionality independent of footwear. T&ST segment revenue rose to £46.1m in H1 2026 (vs £26.2m HY25), with named wins on 787/737/A350, SpaceX and record NA output 2026-08 interim, 2025-08 interim. OKC £14.8m first-half contribution ahead of plan 2026-08 interim.

Key risks (3 bullets)

• Footwear/Nike concentration and transition drag. Nike represented £37m of £77m H1 2025 revenue (~48%); it has fallen to £28.5m in H1 2026 (–23%) and is expected to be lower still through H2 2026 and 2027 as sheet runs down ahead of Vietnam preform ramp 2026-08 interim, 2025-08 interim. Any programme loss or slower Vietnam commissioning materially hits earnings.
• Vietnam commissioning + UK restructuring execution risk. ~$32m Vietnam project with production shared UK↔Vietnam causing "temporary" margin drag; UK collective consultation affects >100 colleagues with material one-off cash costs in H2 2026 2026-08 interim.
• Input-cost and FX volatility. ~90% of sales in non-GBP; Middle East/energy/freight surcharges being applied; H1 2026 net FX unfavourable by £0.4m 2026-08 interim. Continued instability could compress margin faster than surcharges pass through.

Operating leverage

Zotefoams runs a capital-intensive, batch-autoclave manufacturing model. Contribution margin was 60.6% in H1 2026 (HY25: 59.4%), meaning roughly 60p in every incremental £1 of revenue drops before central cost absorption 2026-08 interim. Central costs unallocated to segments (£4.3m in H1 2026, £2.9m in HY25) plus semi-fixed manufacturing overheads sit on top of a large fixed-asset base (PPE £109m, right-of-use £5.8m). North America is a clean example of the effect: revenue +29% to £18.7m, operating margin from 8.3% → 17.6%, with the second low-pressure vessel now fully utilised 2026-08 interim. A 10–20% upside surprise on FY26 revenue (i.e. £19–38m extra) at 40–50% incremental contribution margin (after variable manufacturing costs, some volume-linked SG&A and current start-up drag) plausibly adds £8–19m to operating profit, or roughly 30–70% above the £26.3m PBT consensus — meaningful but not multiples of profit, because the company is currently absorbing dual-site running costs and Vietnam start-up. Once Vietnam is optimised (2028) and UK savings crystallise (£4m), the fixed-cost re-set should raise the through-cycle margin ceiling and lift operating leverage further.

Value-trap signals

None identified. Revenue is growing, dividend is rising (+5.2% interim), leverage is <1×, banking facility was upsized and extended in early 2026, the auditor's H1 2026 review is clean and going concern is not in doubt.

Earnings vs. expectations

• Jan 2025 FY24 update: "ahead of market expectations" — revenue £147.8m vs consensus £145.5m; adj PBT £15.6m vs £14.9m 2025-01 trading update. Beat.
• Aug 2025 H1 25: Board raised full-year underlying PBT guidance "ahead of current market expectations" 2025-08 interim. Beat/guide up.
• Nov 2025 Q3 25: In line with market expectations 2025-11 trading update. In line.
• Jan 2026 FY25 update: revenue £158.5m vs consensus £155.2m; adj PBT £21.1m vs £20.5m 2026-01 trading update. Beat.
• May 2026 trading update: full-year expectations unchanged, +26% YoY revenue growth 2026-05 trading update. In line.
• Aug 2026 H1 26: full-year expectations reiterated 2026-08 interim. In line.

Pattern: consistent beats or meets over the last ~2 years, with the company generally under-guiding and then either raising or delivering. No profit warnings in the covered period.

Conviction

3 — moderate. Disclosure is clean, methodology unambiguous, forward guidance is quantified by the company, and there is an audited FY25 base to anchor from. However, three factors limit conviction: (i) footwear normalisation depth and Vietnam ramp timing are inherently uncertain and swing FY27–28 profit materially; (ii) OKC synergies are early days; (iii) the market-cap upside case leans on hitting the FY29 £40m op-profit ambition, which requires a step-change from today's run-rate.

Anchors: consistent beat-or-meet track record; well-quantified consensus disclosed in filings; strong balance sheet. Limits: transition-period volatility in footwear; execution risk on three simultaneous strategic projects (Vietnam, UK restructuring, OKC integration).

Driver scoring rationale

• AI beneficiary (25): The AI references in the filings are purely internal productivity tools (ZoteIQ, ZoteLabs) — Zotefoams is a spender, not a receiver. T-FIT insulation touches semiconductor cleanrooms and aerospace/space touches some AI-adjacent build-out, but neither is a material or growing AI-driven revenue line. Not an AI-receiver.
• Operating leverage (60): Contribution margin 60.6%, high fixed-cost autoclave base, spare capacity in Poland and coming Vietnam; NA segment margin doubled on volume in H1 2026 — real but sub-software.
• Earnings surprise trend (70): Consistent beats and meets across FY22–FY26 with guidance raises in FY22, FY24 and H1 25.
• Cyclicality (55): Footwear consumer/lifestyle is cyclical, industrial packaging and construction are cyclical, aerospace/space and pharma T-FIT are more defensive. Diversified but net moderately cyclical.
• Moat (55): Proprietary nitrogen-expansion technology, Nike exclusivity to 2029, long product-approval cycles in aerospace — but heavy customer concentration and no dominant network effect.
• Leverage (30): 0.98× net debt/EBITDA, comfortably within 3.5× covenant, £50m headroom on £90m RCF — conservative.
• Earnings quality (70): Clean unqualified reviews, adjusted items well-explained; cash conversion softer in H1 2026 on £14m working-capital build (OKC seasonality + Vietnam inventory) but not aggressive accounting.
• Management quality (60): CEO Ronan Cox delivering the strategy communicated at 2025 CMD; disciplined 7× EBITDA acquisition of OKC; measured Vietnam JV structure with Seoheung de-risking $10m of the $32m project.
• Growth momentum (60): 5-year CAGR mid-teens (revenue), organic growth softening to 4–6% ex-OKC as footwear normalises; medium-term targets imply mid-single-digit organic + M&A.

Overall score rationale

Zotefoams is a good-quality specialty industrial with a fair valuation and strong balance sheet, but it does not fit the AI-receiver thesis — internal AI use only, and no material picks-and-shovels exposure. Operating leverage is real but moderate. Score in the low-to-mid range: interesting quality name at a fair price, but not aligned with the strategy's core pillars.